Clinical Trials Directory

We are doing this study to find the most effective, safe dose of an experimental drug called rilvegostomig (the study drug). We want to know how well the study drug works on its own and when it is used in combination with another anti-cancer drug called datopotamab deruxtecan (also called Dato-DXd). We will compare how well both of these regimens work versus the standard treatment for non-small cell lung cancer (NSCLC) that is ctDNA-positive.

We are doing this study to help women regain bladder strength and function after having their first baby. We want to find out which treatment options work best to stop bladder leakage.

We are doing this study to get a better understanding of why people are at higher risk of developing arthritis after ACL reconstruction surgery. We hope the information from this study can help improve recovery techniques and lower the risk of developing knee arthritis for people who have ACL surgery. We are partnering with UNC-Chapel Hill to do this study.

We are doing this study to evaluate the safety and effectiveness of a drug called isatuximab when it is used in combination with lenalidomide and dexamethasone at lower doses. We want to know if this low dose combination can help patients with multiple myeloma achieve a better response while causing fewer or less severe side effects.

We are doing this study to better understand the unmet sexual health concerns of young adult male cancer survivors.

We are doing this study to learn more about variants in people's genes that cause cells in the back of the eye to function incorrectly and lead to a process called "retinal degeneration."

We are doing this study is to compare the effects of Urolithin A and placebo (an inactive substance with no medicinal properties) on the biological composition of the prostate in men with prostate cancer. In this study, you will have an equal chance of either taking Urolithin A or placebo.

We are doing this study to collect information about our state-of-the-art methods to care for the bladder and kidneys of babies born with spina bifida. We want to compare the results of these methods with other hospitals around the country that are following the same guidelines to protect the bladder and kidney health of infants with spina bifida. We and the other centers following these guidelines will regularly evaluate the outcomes of this care and modify the methods accordingly.